Active Not Recruiting
PHASE3
INTERVENTIONAL
NCT05929066
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.
Interventions
Name:
Retatrutide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Percent Change From Baseline in Body Weight
TimeFrame:
Baseline, Week 80
Description:
Measure:
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score for GOA1 Subset
TimeFrame:
Baseline, Week 80
Description:
Measure:
Change from Baseline in Apnea-Hypopnea Index (AHI) Events Per Hour for GSA1 Subset
TimeFrame:
Baseline, Week 80
Description:
Measure:
Percent Change from Baseline in Body Weight to
TimeFrame:
Baseline, Week 104
Description:
Trial Information
NCT ID
NCT05929066
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025